SCHEMBL13833764

SCHEMBL13833764

Cc1csc2c(=O)n(C)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
BRD4 O60885 2/20 0.33
BRD9 Q9H8M2 2/20 0.33
ERCC5 P28715 2/20 0.33
FEN1 P39748 2/20 0.33
TAF1 P21675 1/20 0.33
BRPF1 P55201 1/20 0.33
CREBBP Q92793 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
PTPN1 P18031 1/20 0.33
CYP2C9 P11712 2/20 0.32
KDM4E B2RXH2 1/20 0.32
KDM6A O15550 1/20 0.32
KDM4A O75164 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM5C P41229 1/20 0.32
KDM2B Q8NHM5 1/20 0.32
DOHH Q9BU89 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
KCNA3 P22001 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15520217 0.81 GAA (0.36) GAABRD4BRD9TAF1BRPF1
SCHEMBL27036824 0.75 GAA (0.32) GAA
SCHEMBL12615717 0.72 CYP2A6 (0.34) ERCC5FEN1KDM4ECYP2A6
SCHEMBL13377367 0.70 BRD4 (0.35) BRD4BRD9ERCC5FEN1KCNA3
SCHEMBL13833648 0.70 ERCC5 (0.40) BRD4BRD9ERCC5FEN1TAF1
SCHEMBL4420462 0.70 CYP2A6 (0.41) KCNA3PDPK1CYP2A6
SCHEMBL18133636 0.66 CYP2A6 (0.39) KCNA3PDPK1CYP2A6
SCHEMBL12279370 0.66 CYP2A6 (0.39) KCNA3PDPK1CYP2A6
SCHEMBL13833812 0.66 PDPK1 (0.49) PDPK1SMN1; SMN2LMNAQPCT
SCHEMBL22306339 0.65 GAA (0.45) GAABRD4BRD9TAF1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2708540-B1 PYRIMIDO-DIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-07-25 EP disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
WO-2012153796-A1 PYRIMIDO-DIAZEPINONE COMPOUND 協和発酵キリン株式会社 (JP) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND REN, AGTR1, KCNJ1 GAA 2227/4885BRD4 102/4885BRD9 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.